- Home
- BCSF vs ORIC Comparison
BCSF vs ORIC Comparison
Compare BCSF & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BCSF | ORIC |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 870.5M | 861.3M |
| IPO Year | 2015 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BCSF | ORIC |
|---|---|---|
| Price | $12.79 | $7.28 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 13 |
| Target Price | $14.00 | ★ $19.73 |
| AVG Volume (30 Days) | 321.1K | ★ 1.5M |
| Earning Date | 05-11-2026 | 05-05-2026 |
| Dividend Yield | ★ 14.61% | N/A |
| EPS Growth | N/A | ★ 19.67 |
| EPS | ★ 0.05 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $264.60 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.82 | $7.23 |
| 52 Week High | $16.00 | $14.93 |
Technical Indicators
Market Signals| Indicator | BCSF | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 40.19 | 37.14 |
| Support Level | $12.49 | N/A |
| Resistance Level | $13.74 | $13.89 |
| Average True Range (ATR) | 0.33 | 0.51 |
| MACD | -0.06 | 0.00 |
| Stochastic Oscillator | 7.79 | 18.46 |
Price Performance
Historical ComparisonAbout BCSF Bain Capital Specialty Finance Inc.
Bain Capital Specialty Finance Inc is an externally managed, closed-end, non-diversified management investment company. The company's objective is to provide risk-adjusted returns and current income to investors by investing in middle-market companies. Its portfolio of investments includes First Lien Senior Secured Loan, Preferred Equity, Equity Interest, Warrants, and Second Lien Senior Secured Loan, and others.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.